Ascentage Pharma Group International (AAPG) Current Deferred Revenue (2023 - 2025)
Historic Current Deferred Revenue for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q2 2025 value amounting to $5.2 million.
- Ascentage Pharma Group International's Current Deferred Revenue changed N/A to $5.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $5.1 million for FY2024, which is 9795.57% down from last year.
- According to the latest figures from Q2 2025, Ascentage Pharma Group International's Current Deferred Revenue is $5.2 million.
- In the past 5 years, Ascentage Pharma Group International's Current Deferred Revenue ranged from a high of $5.3 million in Q4 2023 and a low of $5.2 million during Q4 2024
- For the 3-year period, Ascentage Pharma Group International's Current Deferred Revenue averaged around $5.3 million, with its median value being $5.2 million (2025).
- Data for Ascentage Pharma Group International's Current Deferred Revenue shows a peak YoY increase of 217.75% (in 2024) and a maximum YoY decrease of 217.75% (in 2024) over the last 5 years.
- Over the past 3 years, Ascentage Pharma Group International's Current Deferred Revenue (Quarter) stood at $5.3 million in 2023, then fell by 2.18% to $5.2 million in 2024, then rose by 0.28% to $5.2 million in 2025.
- Its Current Deferred Revenue stands at $5.2 million for Q2 2025, versus $5.2 million for Q4 2024 and $5.3 million for Q4 2023.